Gu Xiaorong, Hu Zhenbo, Ebrahem Quteba, Crabb John S, Mahfouz Reda Z, Radivoyevitch Tomas, Crabb John W, Saunthararajah Yogen
From the Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, and.
Department of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195 and.
J Biol Chem. 2014 May 23;289(21):14881-95. doi: 10.1074/jbc.M114.562447. Epub 2014 Apr 2.
Gene activation requires cooperative assembly of multiprotein transcription factor-coregulator complexes. Disruption to cooperative assemblage could underlie repression of tumor suppressor genes in leukemia cells. Mechanisms of cooperation and its disruption were therefore examined for PU.1 and RUNX1, transcription factors that cooperate to activate hematopoietic differentiation genes. PU.1 is highly expressed in leukemia cells, whereas RUNX1 is frequently inactivated by mutation or translocation. Thus, coregulator interactions of Pu.1 were examined by immunoprecipitation coupled with tandem mass spectrometry/Western blot in wild-type and Runx1-deficient hematopoietic cells. In wild-type cells, the NuAT and Baf families of coactivators coimmunoprecipitated with Pu.1. Runx1 deficiency produced a striking switch to Pu.1 interaction with the Dnmt1, Sin3A, Nurd, CoRest, and B-Wich corepressor families. Corepressors of the Polycomb family, which are frequently inactivated by mutation or deletion in myeloid leukemia, did not interact with Pu.1. The most significant gene ontology association of Runx1-Pu.1 co-bound genes was with macrophages, therefore, functional consequences of altered corepressor/coactivator exchange were examined at Mcsfr, a key macrophage differentiation gene. In chromatin immunoprecipitation analyses, high level Pu.1 binding to the Mcsfr promoter was not decreased by Runx1 deficiency. However, the Pu.1-driven shift from histone repression to activation marks at this locus, and terminal macrophage differentiation, were substantially diminished. DNMT1 inhibition, but not Polycomb inhibition, in RUNX1-translocated leukemia cells induced terminal differentiation. Thus, RUNX1 and PU.1 cooperate to exchange corepressors for coactivators, and the specific corepressors recruited to PU.1 as a consequence of RUNX1 deficiency could be rational targets for leukemia differentiation therapy.
基因激活需要多蛋白转录因子 - 共调节因子复合物的协同组装。协同组装的破坏可能是白血病细胞中肿瘤抑制基因被抑制的基础。因此,研究了PU.1和RUNX1这两种协同激活造血分化基因的转录因子的协同作用机制及其破坏情况。PU.1在白血病细胞中高表达,而RUNX1经常因突变或易位而失活。因此,通过免疫沉淀结合串联质谱/蛋白质印迹法,在野生型和Runx1缺陷型造血细胞中检测了Pu.1的共调节因子相互作用。在野生型细胞中,共激活因子的NuAT和Baf家族与Pu.1共免疫沉淀。Runx1缺陷导致与Pu.1相互作用显著转向与Dnmt1、Sin3A、Nurd、CoRest和B - Wich共抑制因子家族。在髓系白血病中经常因突变或缺失而失活的多梳家族共抑制因子不与Pu.1相互作用。Runx1 - Pu.1共结合基因最显著的基因本体关联与巨噬细胞有关,因此,在关键的巨噬细胞分化基因Mcsfr处研究了共抑制因子/共激活因子交换改变的功能后果。在染色质免疫沉淀分析中,Runx1缺陷并未降低Pu.1与Mcsfr启动子的高水平结合。然而,在该位点,Pu.1驱动的从组蛋白抑制标记到激活标记的转变以及终末巨噬细胞分化均显著减少。在RUNX1易位的白血病细胞中,抑制DNMT1而非抑制多梳家族,可诱导终末分化。因此,RUNX1和PU.1协同作用以将共抑制因子换成共激活因子,并且由于Runx1缺陷而招募到PU.1的特定共抑制因子可能是白血病分化治疗的合理靶点。